Introduction
Lung complications are an important cause of morbidity and mortality in hemopoietic stem cell transplantation (HSCT) recipients. These include conditioning toxicity, infective complications and bronchiolitis obliterans (BO). 1 The incidence of BO in HSCT survivors varies from 6 to 20%. The disease is characterized histologically by obliteration and destruction of the lumena of respiratory bronchioles, and clinically by idiopathic deterioration in the forced expiratory volume (FEV), with or without bronchodilator response. There is a documented association with age, graft-versus-host disease (GVHD), total body irradiation (TBI) and prior chemotherapy exposure. 2 The disease often runs a refractory and fatal course, and is the commonest cause of late mortality after allogeneic HSCT. 3 Cilia are minute hair-like structures on the respiratory mucosa, which beat continuously at 10-18 Hz, and create a constant flow of periciliary fluid maintaining the sterility of the lower respiratory tract. Dysfunction of respiratory cilia (e.g. Kartagener syndrome) leads to the development of recurrent respiratory tract infections, bronchiectasis and small airway obstruction. Ciliary defects have been retrospectively investigated in recipients of HSCT. One report of nasal ciliary assessment in post-HSCT patients with sinusitis showed a high incidence of ultrastructural abnormalities. 4 Our group has previously reported reduced ciliary beat frequency (CBF) in patients with BO. 5 However, it is unclear whether the reduced CBF predated respiratory deterioration or was related to structural ciliary damage. We therefore embarked on a prospective study of regular ciliary monitoring in consecutive patients receiving autologous and allogeneic HSCT. This aimed to study the effect of conditioning therapy and GVHD on ciliary structure and function, and its consequent influence on lung function and development of BO.
Materials and methods
Lung function tests were performed according to standard protocols, and results for forced expiratory volume in 1 s (FEV 1 ), mid expiratory flow at 25-75% of vital capacity (FEF 25-75%) and forced vital capacity (FVC) were expressed as a percent of predicted values. 6 Clinical definitions were used to define and grade BO and GVHD. 7, 8 BO was defined as small airway obstruction in the absence of asthma and chronic obstructive pulmonary disease, 9 and classified as severe (FEV 1 o50%), moderate (FEV 1 51-65%) and mild (FEV 1 66-80%). 7, 9 With informed consent, nasal epithelium was collected from the inferior turbinates with a cytology brush without anesthetic, at pre-HSCT and 3, 6, 9 and 12 months after HSCT. The ciliated epithelium was re-suspended in 1.5 ml of medium 199 (Flow Laboratory, New York, NY, USA) and examined by phase-contrast microscopy ( Â 400, 371C stage, Leica DM LB, Wetzlar, Germany). The frequency of light interruption was conveyed to an multi-purpose vehicle (MPV)-COMBI photo-multiplier (Leica) and translated into CBF (Hz). 10 For transmission electron microscopy (TEM), all appropriately orientated ciliary samples are examined for cilia matrix, membrane and 9 þ 2 microtubular structure ( Figure 1 ). The following were classified as abnormal: dis-arranged, extra-tubule, single tubule, bleb on membrane, extra-matrix, and '8 þ 2' structure and compounds (Figures 2 and 3) . Abnormality ratio was expressed as the percentage of total cilia assessed. Results from 40 healthy age and gender-matched volunteers from a previous study were used as controls. 11 The median CBF in the control group was 13.5 Hz, and the overall percentage of structurally abnormal cilia was 18.4%. Patients with BO and GVHD were treated irrespective of the ciliary study results and computerized patient records were reviewed for episodes of fever and chest infection. Statistical analysis was performed using SPSS 11.0 (Chicago, IL, USA) using non-parametric methods. The study protocol was approved by the institution ethics committee.
Results
The subjects included 11 men and eight women at a median age of 38 years (range 19-55 years). The underlying diagnoses were acute myeloid leukemia (AML, n ¼ 3), acute lymphoblastic leukemia (ALL, n ¼ 3), chronic myeloid leukemia (CML, n ¼ 7) multiple myeloma (MM, n ¼ 2) and lymphoma (NHL, n ¼ 4). Autologous and allogeneic HSCTs were performed in three (cases 1-3) and 16 cases (cases [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , respectively, and involved unrelated donors in six cases (cases [14] [15] [16] [17] [18] [19] . Four male patients (cases 1, 6, 9, 15) were ex-smokers for 1-12 years before HSCT. Conditioning regimens included TBI (n ¼ 8, 12 Gy for myeloablation, 3 Gy for non-myeloablation case 12) and non-TBI (n ¼ 11) protocols. GVHD prophylaxis was cyclosporine and methotrexate (substituted by mycophenolate mofetil for case 12).
At the time of HSCT, the median CBF was 10.88 Hz (range 7.98-12.82 Hz), and was not significantly related to
This was, however, significantly lower (Po0.001) than the CBF of an age-and sex-matched population of normal volunteers (median 13.5 Hz, range 9.6-17.0). Structural ciliary studies were performed on 18 cases, except case 4, in which TEM analysis was unsuccessful. There was a wide range of success in terms of ciliary harvest and TEM assessment. The median numbers of cilia harvested and examined were 320 (range 38-664) and 207 (range 21-441), respectively. The median percentage of cilia with one or more abnormalities was 15.1% (range 4.5-42.8%). The percentage of abnormal cilia was unrelated to the number of cilia harvested (P ¼ 0.8) or the CBF (P ¼ 0.42). The baseline abnormal cilia percentage was also unrelated to age (P ¼ 0.32), sex (P ¼ 0.16), FEV 1 (P ¼ 0.21), smoking history (P ¼ 0.16) or diagnosis (P ¼ 0.36). Serial assessments could not be performed for cases 17 and 19 owing to early death. In the remaining 17 cases, a total of 51 assessments were made, as limited by bleeding, thrombocytopenia and patient discomfort. In cases 7 and 8, complete denudation of the turbinates precluded ciliary TEM and CBF assessment (Figure 4 ). For the remaining 15 cases, the median number of cilia in subsequent harvests was comparable to pre-HSCT (median 291, range 10-674, P ¼ 0.51). In each individual case, there was a wide variation in CBF and FEV at interval follow-ups ( Table 1) . The CBF at 0, 3, 6, 9 and 12 months assessments showed no significant correlation for any pair of assessments (P ¼ 0.13-0.91). All intervals FEV 1 assessments, however, were significantly correlated with pre-HSCT FEV 1 (P ¼ 0.01 to Po0.001). Comparing paired pre-and post-HSCT results, there was a significant decline in CBF at 
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Normal ciliated respiratory epithelia Denuded respiratory epithelia Figure 4 Electron microgram of (a) normal and (b) denuded (arrow) epithelium in one case. Cilia, electron microscopy and bronchiolitis obliterans 1 year (P ¼ 0.031, Wilcoxon), but a trend to improved FEV 1 (P ¼ 0.058, Wilcoxon). At 1 year, there was no significant difference in FEV 1 and CBF (or change in FEV 1 and CBF) between cases receiving autologous or allogeneic HSCT, with or without TBI exposure, and with or without GVHD or BO (data not shown). However, the small number of cases and events severely limits the power of the analysis. Only cases 10 and 12 developed mild BO at 1 year (FEV 1 79 and 69%), and in case 12, this was accompanied by deterioration in CBF. The percentage of structurally abnormal cilia also increased significantly by 1 year (P ¼ 0.003, Wilcoxon). However, neither cases 10 and 12 showed more cilia damage. Nine patients had a history of hospital admission and intravenous antibiotic treatment of pneumonic episodes (range 1-3 admissions) during the study period. Compared with patients without documented pneumonia, there were no differences in terms of CBF at diagnosis (P ¼ 0.24) or at 1-year follow-up (P ¼ 0.28), in terms of the percentage of abnormal cilia either at diagnosis (P ¼ 0.59) or at 1 year (P ¼ 0.22). Subsequent clinical courses are shown in Table 1 . At 40 months follow-up, three further cases died of leukemia relapse. Among 14 survivors, the FEV 1 was within normal limits for 12 cases, including three patients (cases 8, 13 and 15) receiving inhalational steroids for interval drop in FEV 1 (o80% normal). The transient deterioration in case 8 may be attributed to severe acute respiratory distress syndromes (SARs). 12 Case 12 (with lowest FEV 1 at 1 year) has improved back to normal range. Case 10 continued to have mild BO, whereas case 14 developed sudden onset of severe BO at 18 months, despite a completely normal FEV 1 and CBF at 1 year. His respiratory function remained poor after recurrent fungal and atypical mycobacterial pneumonia and he is currently on the lung transplant waiting list.
Discussion
Bronchiolitis obliterans is the most significant pulmonary cause of morbidity and mortality among HSCT survivors, and contributes up to one-third of deaths. 13, 14 The actuarial incidence of BO after HSCT may be up to 20%, 15 but is lower in more recent surveys. 1 Immune-mediated destruction of small airways causing obstructive lung defect is the hallmark of the disease. BO is also found after lung transplantation, but is rare after autologous HSCT. 2, 16 For lung transplant recipients, it is known that early transient reversible ciliary dysfunction is common 17 and persists only in BO cases with chronic rejection. 18 In HSCT patients, GVHD against the native lung may similarly depress mucociliary clearance, stagnate respiratory mucus and cause a vicious cycle. 19, 20 Diagnosis and monitoring of post-HSCT BO are best carried by serial lung function tests. 21 However, clinical prediction on the occurrence and severity of BO is difficult. 22 Patients either run a static course with permanent residual pulmonary defect despite inhalational and systemic immunosuppressant or a relentless deteriorating course culminating in death or lung transplantation. 15, 23 Respiratory ciliary function and structure are rarely studied in HSCT recipients owing to technical difficulties. In one Caucasian study, CBF was reported to be within normal range in most HSCT recipients, but a high incidence of structural abnormalities was reported. 4 Our group has demonstrated retrospectively in a larger cohort of Chinese patients that reduced CBF is common after allogeneic HSCT, and is associated with BO and GVHD. 5 However, baseline and serial CBF were not measured in the retrospective study, and many patients already had endstage BO. Hence, it was not possible to define a cause and effect relationship between reduced CBF and BO. Furthermore, ciliary structural studies were not performed.
The current prospective study showed, for the first time, that pre-HSCT CBF abnormalities are common. This difference was only apparent when compared with a matched control group, as the normal range of CBF showed a wide age-related spread. 11, 24, 25 The greater pre-HSCT respiratory compromise may partly be owing to the inclusion of more acute leukemia and lymphoma cases, with more intensive chemotherapy exposure. 26 Our results also showed reduced CBF after HSCT, regardless of GVHD occurrence and its treatment, but failed to show significant correlation with respiratory compromise. One possibility may be that the monitoring period is too early for BO to develop. However, even in patients with incipient BO, CBF depression was not marked. This may not be surprising as nasal sampling only give limited information on lower respiratory tract mucociliary clearance, which in turn is only one aspect of pulmonary defense and immunity. Hence, our results cannot provide strong evidence for ciliary function defect as the cause of small airway damage. It also did not support regular CBF monitoring within the first year after HSCT.
Squamous metaplasia and ciliary denudation have been noted in the previous report of ciliary assessment in HSCT cases. 4 Its repeated presence in our post-HSCT assessments probably represented severe upper respiratory mucosa damage. However, the significance of the other structural abnormalities is less certain as they are common in healthy subjects. 24, 27, 28, 29 Indeed, the incidence of pre-HSCT structural ciliary deficiency was not higher than in a matched control local population. Our serial structural assessment did show an increase in structural damage to the cilia after HSCT, but the percentage of abnormalities did not relate to lung function, GVHD or ciliary function. Based on these results, we do not recommend routine SEM assessment in HSCT recipients. However, we must emphasize that these findings were based on a small number of patients, early after HSCT. A longer follow-up of a larger number of patients capturing more BO events may be needed for results to be conclusive.
